Monte Rosa Therapeutics (NASDAQ:GLUE) reported Phase 1 results for MRT-8102, a NEK7-directed molecular glue degrader, and said it plans to advance the drug into three Phase 2 studies. In the four-week GFORCE-1 study, 108 obese participants with elevated cardiovascular disease risk received daily doses of 5 mg, 20 mg, 40 mg or placebo, followed by four weeks of safety tracking. MRT-8102 produced 80% to 90% median NEK7 degradation across dose groups and lowered median hsCRP by 85%, IL-6 by 54%, calprotectin by 56%, SAA by 51% and S100A12 by 46%. The treatment also reduced lipoprotein(a) by 24% without raising LDL-C or triglycerides, while fibrinogen fell 28%. Among participants with elevated baseline levels, HMGB1 declined 40% and IL-1β declined 37%. Monte Rosa plans to begin the GEMINI-1 gout study in late 2026 or early 2027, with initial data expected in the second half of 2027, and to launch the GFORCE-2 Phase 2b coronary artery disease study and GALAXY-1 hidradenitis suppurativa study in early 2027. Shares were down 6.41% at $11.17 at publication, after rising 20.03% to $14.32 in premarket trading ahead of the data update.